Clinical Trial Update: Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA) [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating EC17, a folate-fluorescein imaging agent, for intraoperative visualization of lung cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Lung Cancer

Drugs mentioned

• EC17 (folate-hapten conjugate)

Snippet

Sponsor: University of Pennsylvania | Conditions: Lung and Pleural Malignancies, Neoplasms | Phase 1 | Status: COMPLETED